With new investor backing, the company prepares a £25m Series A to move its lead tauC3 antibody into human trials.

longevity.technology/news/tauc3-b...

#Neurodegeneration #TauProtein #Biotech #FrontotemporalDementia #BrainTherapy #longevity #TauC3 #Innovation #ClinicalResearch